AllPennyStocks.com EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate

EyePoint posted the results for its Phase 3 Lugano trial, which compared its Duravyu therapy with Aflibercept, the standard treatment for wet AMD.

Other Penny Stock Movers

Sub-Dollar Cancer Diagnostics Play Erupts on Q2 Revenue
Target Expansion and Geophysics Survey Trigger 18% Surge for Norwegian Base-Metal Project
BC Copper Explorer Hits Native Copper and Potassic Alteration in Phase II Drilling
Most Popular
{{ index + 1 }}


Back to Top